Groupe Hospitalier Du Havre
- Address
- 55 B Rue Gustave Flaubert, 76600 Le Havre, France
Groupe Hospitalier Du Havre
Groupe Hospitalier Du Havre is a distinguished medical research center engaged in diverse clinical investigations spanning critical care, cardiovascular medicine, oncology, and immune-mediated diseases. The institution demonstrates particular expertise in septic shock management, interventional cardiology, and multiple myeloma therapeutics, conducting pivotal trials that advance treatment paradigms across multiple medical specialties.
- Critical care research focusing on septic shock with hypercontractility and novel cardiac rate control strategies
- Cardiovascular interventions including dual antiplatelet therapy optimization in elderly patients undergoing percutaneous coronary intervention
- Hematologic malignancies with emphasis on multiple myeloma treatment strategies, including novel bispecific antibody combinations and MRD-adapted approaches
- Respiratory medicine investigating severe asthma, COPD exacerbation prevention, and biologic therapy optimization
The center actively participates in international multicenter trials evaluating autoimmune conditions such as rheumatoid arthritis, cutaneous lupus erythematosus, and pulmonary arterial hypertension. Additional research programs encompass metabolic disorders including gout and type 1 diabetes with gastroparesis, as well as cerebrovascular disease prevention and high-grade glioma treatment. This comprehensive portfolio positions Groupe Hospitalier Du Havre as a versatile contributor to evidence-based medicine across acute and chronic disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Groupe Hospitalier Du Havre
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Cardiovascular Safety of Cagrilintide and Semaglutide in Participants with Established Cardiovascular Disease | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2023 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 1 | Unknown | 2023-02-28 | 2023-02-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.